Proteomic Analysis of Cerebrospinal Fluid in Pediatric Acute Lymphoblastic Leukemia Patients: a Pilot Study

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2019 Jun 14

PMID 31190885

Citations 10

Authors

Linghong Guo

Honghong Ren

Hao Zeng

Yanqiu Gong

Xuelei Ma

Affiliations

Soon will be listed here.

Abstract

Purpose: Involvement of central nervous system in acute lymphoblastic leukemia (CNSL) remains one of the major causes of pediatric acute lymphoblastic leukemia (ALL) treatment failure. However, the current understanding of the pathological process of CNSL is still limited. This study aimed to better understand the protein expression in cerebrospinal fluid (CSF) of ALL and discover valuable prognostic biomarkers.

Materials And Methods: CSF samples were obtained from ALL patients and healthy controls. Comparative proteomic profiling using label-free liquid chromatography-tandem mass spectrometry was performed to detect differentially expressed proteins.

Results: In the present study, 51 differentially expressed proteins were found. Among them, two core clusters including ten proteins (TIMP1, LGALS3BP, A2M, FN1, AHSG, HRG, ITIH4, CF I, C2, and C4a) might be crucial for tumorigenesis and progression of ALL and can be potentially valuable indicators of CNSL.

Conclusion: These differentially expressed proteins of ALL children with central nervous system involvement and normal children may work as diagnostic and prognostic factors of ALL patients.

Citing Articles

Deep Proteome Analysis of Cerebrospinal Fluid from Pediatric Patients with Central Nervous System Cancer.

Mirian C, Ostergaard O, Thastrup M, Modvig S, Foss-Skiftesvik J, Skjoth-Rasmussen J J Proteome Res. 2024; 23(11):5048-5063.

PMID: 39382389 PMC: 11536435. DOI: 10.1021/acs.jproteome.4c00471.

Mass spectrometry-based proteomics of cerebrospinal fluid in pediatric central nervous system malignancies: a systematic review with meta-analysis of individual patient data.

Mirian C, Thastrup M, Mathiasen R, Schmiegelow K, Olsen J, Ostergaard O Fluids Barriers CNS. 2024; 21(1):14.

PMID: 38350915 PMC: 10863112. DOI: 10.1186/s12987-024-00515-x.

Proteomics in Childhood Acute Lymphoblastic Leukemia: Challenges and Opportunities.

Kourti M, Aivaliotis M, Hatzipantelis E Diagnostics (Basel). 2023; 13(17).

PMID: 37685286 PMC: 10487225. DOI: 10.3390/diagnostics13172748.

Engineered extracellular matrices facilitate brain organoids from human pluripotent stem cells.

Muniz A, Topal T, Brooks M, Sze A, Kim D, Jordahl J Ann Clin Transl Neurol. 2023; 10(7):1239-1253.

PMID: 37283238 PMC: 10351667. DOI: 10.1002/acn3.51820.

Mass Spectrometry Contribution to Pediatric Cancers Research.

Agostini M, Traldi P, Hamdan M Medicina (Kaunas). 2023; 59(3).

PMID: 36984613 PMC: 10053507. DOI: 10.3390/medicina59030612.

References

Luparello C, Avanzato G, Carella C, Pucci-Minafra I . Tissue inhibitor of metalloprotease (TIMP)-1 and proliferative behaviour of clonal breast cancer cells. Breast Cancer Res Treat. 1999; 54(3):235-44. DOI: 10.1023/a:1006121129382. View

Masliah E, Ho G, Wyss-Coray T . Functional role of TGF beta in Alzheimer's disease microvascular injury: lessons from transgenic mice. Neurochem Int. 2001; 39(5-6):393-400. DOI: 10.1016/s0197-0186(01)00046-8. View

Marchetti A, Tinari N, Buttitta F, Chella A, Angeletti C, Sacco R . Expression of 90K (Mac-2 BP) correlates with distant metastasis and predicts survival in stage I non-small cell lung cancer patients. Cancer Res. 2002; 62(9):2535-9. View

Gasque P, Julen N, Ischenko A, Picot C, Mauger C, Chauzy C . Expression of complement components of the alternative pathway by glioma cell lines. J Immunol. 1992; 149(4):1381-7. View

Grassadonia A, Tinari N, Iurisci I, Piccolo E, Cumashi A, Innominato P . 90K (Mac-2 BP) and galectins in tumor progression and metastasis. Glycoconj J. 2004; 19(7-9):551-6. DOI: 10.1023/B:GLYC.0000014085.00706.d4. View

Hawthorn L, Stein L, Varma R, Wiseman S, Loree T, Tan D . TIMP1 and SERPIN-A overexpression and TFF3 and CRABP1 underexpression as biomarkers for papillary thyroid carcinoma. Head Neck. 2004; 26(12):1069-83. DOI: 10.1002/hed.20099. View

Hegedus C, Gunn L, Skibola C, Zhang L, Shiao R, Fu S . Proteomic analysis of childhood leukemia. Leukemia. 2005; 19(10):1713-8. DOI: 10.1038/sj.leu.2403897. View

Kossakowska A, Urbanski S, Edwards D . Tissue inhibitor of metalloproteinases-1 (TIMP-1) RNA is expressed at elevated levels in malignant non-Hodgkin's lymphomas. Blood. 1991; 77(11):2475-81. View

Ganter U, Strauss S, Jonas U, Weidemann A, Beyreuther K, Volk B . Alpha 2-macroglobulin synthesis in interleukin-6-stimulated human neuronal (SH-SY5Y neuroblastoma) cells. Potential significance for the processing of Alzheimer beta-amyloid precursor protein. FEBS Lett. 1991; 282(1):127-31. DOI: 10.1016/0014-5793(91)80460-k. View

10.

Suminoe A, Matsuzaki A, Hattori H, Koga Y, Ishii E, Hara T . Expression of matrix metalloproteinase (MMP) and tissue inhibitor of MMP (TIMP) genes in blasts of infant acute lymphoblastic leukemia with organ involvement. Leuk Res. 2007; 31(10):1437-40. DOI: 10.1016/j.leukres.2007.01.015. View

11.

Klaska I, Nowak J . [The role of complement in physiology and pathology]. Postepy Hig Med Dosw (Online). 2007; 61:167-77. View

12.

Okroj M, Hsu Y, Ajona D, Pio R, Blom A . Non-small cell lung cancer cells produce a functional set of complement factor I and its soluble cofactors. Mol Immunol. 2007; 45(1):169-79. DOI: 10.1016/j.molimm.2007.04.025. View

13.

Roy S, Josephson S, Fridlyand J, Karch J, Kadoch C, Karrim J . Protein biomarker identification in the CSF of patients with CNS lymphoma. J Clin Oncol. 2007; 26(1):96-105. PMC: 4134101. DOI: 10.1200/JCO.2007.12.1053. View

14.

Wurtz S, Schrohl A, Mouridsen H, Brunner N . TIMP-1 as a tumor marker in breast cancer--an update. Acta Oncol. 2008; 47(4):580-90. DOI: 10.1080/02841860802022976. View

15.

Shi L, Zhang J, Wu P, Feng K, Li J, Xie Z . Discovery and identification of potential biomarkers of pediatric acute lymphoblastic leukemia. Proteome Sci. 2009; 7:7. PMC: 2662805. DOI: 10.1186/1477-5956-7-7. View

16.

Kalabay L, Cseh K, Benedek S, Fekete S, Masszi T, Herjeczki K . Serum alpha 2-HS glycoprotein concentration in patients with hematological malignancies. A follow-up study. Ann Hematol. 1991; 63(5):264-9. DOI: 10.1007/BF01698376. View

17.

Scrideli C, Cortez M, Yunes J, Queiroz R, Valera E, da Mata J . mRNA expression of matrix metalloproteinases (MMPs) 2 and 9 and tissue inhibitor of matrix metalloproteinases (TIMPs) 1 and 2 in childhood acute lymphoblastic leukemia: potential role of TIMP1 as an adverse prognostic factor. Leuk Res. 2009; 34(1):32-7. DOI: 10.1016/j.leukres.2009.10.007. View

18.

Sirvent N, Suciu S, Rialland X, Millot F, Benoit Y, Plantaz D . Prognostic significance of the initial cerebro-spinal fluid (CSF) involvement of children with acute lymphoblastic leukaemia (ALL) treated without cranial irradiation: results of European Organization for Research and Treatment of Cancer (EORTC).... Eur J Cancer. 2010; 47(2):239-47. DOI: 10.1016/j.ejca.2010.10.019. View

19.

van den Broek I, Sparidans R, van Winden A, Gast M, van Dulken E, Schellens J . The absolute quantification of eight inter-α-trypsin inhibitor heavy chain 4 (ITIH4)-derived peptides in serum from breast cancer patients. Proteomics Clin Appl. 2010; 4(12):931-9. DOI: 10.1002/prca.201000035. View

20.

Rolny C, Mazzone M, Tugues S, Laoui D, Johansson I, Coulon C . HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell. 2011; 19(1):31-44. DOI: 10.1016/j.ccr.2010.11.009. View